Glucomannan for Weight Loss: What the Trials Show

Paid links: Some links in this article go to iHerb through an affiliate program: if you buy something after clicking one, StarterScience earns a commission and you pay the same price. That commission never changes how we describe the evidence, including when the evidence is weak. This article is general information, not medical advice — talk to a qualified healthcare professional before starting any supplement.

Glucomannan is a soluble fibre from the konjac tuber that swells into a thick gel on contact with water. The sales pitch writes itself: swallow it before a meal, feel full, eat less. The trials are less obliging. Five pooled analyses published since 2008 put the average difference between glucomannan and placebo between essentially zero and about 1.4 kg — and the one trial that measured appetite directly found no change in how hungry or full people said they felt, and no weight loss either.

That does not make glucomannan a scam. It makes it a fibre with a solid cholesterol effect, a modest laxative effect, a real choking and obstruction risk if taken carelessly, and a weight-loss effect somewhere between "too small to notice on a bathroom scale" and "not there". Here are the numbers, so you can decide which of those you are paying for.

What the pooled trial data actually says

Reading the pooled analyses side by side is more informative than reading any one of them, because the estimate has moved as trial quality and scrutiny improved. In every row except the 2015 correction, a negative number means glucomannan did better; that one paper reverses the sign, as its own figure legend states.

Two details matter more than the headline numbers. The Bessell review pre-specified what would count as a worthwhile result — a 2.5 kg advantage over placebo — and reported that of every isolated compound it pooled, "none met our threshold for clinical significance (≥2.5 kg)." Glucomannan's 1.27 kg did not clear it. And the 2023 network meta-analysis graded the glucomannan evidence low certainty, meaning the true effect could plausibly be quite different from the estimate.

The individual trials are noisier than the pooled figures suggest, in both directions. The 2015 Zalewski review found three of its six RCTs reporting significant weight reduction on glucomannan, at scattered time points: week 2 (MD 0.21 kg, 95% CI 0.13–0.29), week 4 (MD 2.04 kg, 95% CI 0.52–3.56), week 5 (MD 1.3 kg, 95% CI 0.89–1.71) and week 8 (MD 3.17 kg, 95% CI 1.29–5.05). But "only one RCT reported a beneficial effect at more than one point", and "none of the RCTs reported a favorable effect of GM on BMI." Small trials producing results several times the pooled estimate, at inconsistent time points, with no matching BMI effect, is the signature of an unstable signal rather than a solid one.

One trial is worth reading on its own, because it registered its design in advance (NCT00613600) and measured appetite directly rather than inferring it. Keithley and colleagues randomised 53 overweight and moderately obese adults (BMI 25–35) to 1.33 g of glucomannan or an identical placebo capsule with 236.6 mL of water, one hour before each of three meals — 3.99 g a day, above the dose the EU weight-loss claim is built on — for eight weeks. Their conclusion: glucomannan "did not promote weight loss or significantly alter body composition, hunger/fullness, or lipid and glucose parameters."

Where the number everyone quotes comes from

Search for glucomannan and you will repeatedly meet a figure around 5.5, often rendered as "5.5 kg of weight loss." It traces to a single 1984 trial by Walsh and colleagues in the International Journal of Obesity: 20 obese subjects, eight weeks, 1 g in two 500 mg capsules with 8 oz of water an hour before each meal. The reported result was "a significant mean weight loss (5.5 lbs)". Pounds, not kilograms — about 2.5 kg, in twenty people, forty-two years ago. Anyone quoting 5.5 kg has silently doubled a four-decade-old result from a study smaller than most office departments.

The literature has also had to correct itself in public, and that correction is the single most useful thing to know about this evidence base. The 2015 Zalewski review reported a statistically significant two-week weight advantage for glucomannan. A correction published in the same journal later that year — co-authored by the original reviewers, a statistics group and one of the trialists — found that the standard deviations taken from the Keithley trial were wrong, and wrong in the trial paper itself: "We found that the SDs from both papers were incorrect." The correct eight-week values were 1.91 and 1.62, against published figures roughly an order of magnitude smaller. BMI values were also "initially calculated and reported inappropriately." After the fix the two-week effect "turned out to be insignificant", and the corrected two-week BMI result was statistically significant in favour of placebo (MD −0.27, 95% CI −0.43 to −0.11). A citation of the 2015 review without its correction is out of date.

The satiety story has a hole in it

The mechanism is genuinely plausible. Konjac glucomannan "has very substantial water-holding properties, and forms highly viscous solutions when dissolved in water", expanding "rapidly to many times the size of the original material" — properties that, in the words of one clinical toxicology report, have "made glucomannan an ideal diet agent as the material swells in the GI tract after ingestion, producing a feeling of satiety and fullness." European regulators found that convincing enough to authorise a claim, on condition that consumers are told "the beneficial effect is obtained with a daily intake of 3 g of glucomannan in three doses of 1 g each, together with 1-2 glasses of water, before meals and in the context of an energy-restricted diet."

What is missing is direct confirmation that people actually feel fuller. The Keithley trial measured hunger and fullness alongside weight and found no significant difference on those outcomes either. The honest position: the physical behaviour of the fibre is real, the appetite endpoint did not move in the trial that measured it, and if you are shopping for an appetite suppressant, glucomannan is not a reliable one.

What glucomannan is genuinely good at

The cholesterol evidence is a different quality of evidence entirely, and it is the reason to take this fibre seriously at all. A 2017 meta-analysis in the American Journal of Clinical Nutrition pooled 12 randomised trials (n = 370, eight in adults and four in children) of konjac glucomannan specifically. LDL cholesterol fell by 0.35 mmol/L (95% CI −0.46 to −0.25) and non-HDL cholesterol by 0.32 mmol/L (95% CI −0.46 to −0.19); apolipoprotein B did not shift in the six trials measuring it. The authors' summary supports "the intake of ∼3 g KJM/d for reductions in LDL cholesterol and non-HDL cholesterol of 10% and 7%, respectively." A 10% LDL reduction from a fibre is a meaningful cardiometabolic result — considerably more interesting than the weight number.

The 2008 meta-analysis pointed the same way: total cholesterol −19.28 mg/dL, LDL −15.99 mg/dL, triglycerides −11.08 mg/dL and fasting glucose −7.44 mg/dL, with no effect on HDL or blood pressure. Even the 2019 paediatric trial that found no weight effect reported "lower total and low-density lipoprotein cholesterol concentrations at 12 weeks."

For bowel regularity the picture is real but smaller than marketing implies. A 2017 meta-analysis of glucomannan for functional constipation in children pooled three trials with 122 participants: defecation frequency rose (MD 1.40 per week, 95% CI 0.36 to 2.44, p = 0.008), but stool consistency did not significantly improve (SMD 0.48, 95% CI −0.44 to 1.40) and neither did the rate of successful treatment (RR 1.36, 95% CI 0.48 to 3.81).

Three regulators, three different answers

What health authorities will and will not let a label say shows how contested this is.

• European Union / retained UK law. Two claims are authorised: "Glucomannan contributes to the maintenance of normal blood cholesterol levels" at a daily intake of 4 g, and "Glucomannan in the context of an energy restricted diet contributes to weight loss" at 3 g/day in three 1 g doses. Both entries carry a mandatory "warning of choking to be given for people with swallowing difficulties or when ingesting with inadequate fluid intake."
• Canada. Health Canada's monograph, dated 26 July 2024, permits claims that glucomannan "helps to lower cholesterol levels", acts as a bulk-forming laxative and gives "gentle relief of constipation and/or irregularity". There is no permitted weight-loss claim at all. The dose table covers only cholesterol lowering (1–1.5 g three times daily) and laxative use (0.5–5 g three times daily), for "Adults 18 years and older".
• United States. Glucomannan is sold as a dietary supplement, so no efficacy review happens before sale. What the FDA regulates is the warning label on drug products containing it — see the next section.

One regulator authorises a weight-loss claim, another declines to list one, a third does not review the question at all. That spread is itself the finding: it is what you expect when an effect is small and inconsistently reproduced.

The safety section most glucomannan pages skip

A fibre that expands to many times its volume can cause harm in a way that a vitamin capsule cannot. This is not theoretical; it is written into US federal regulation. 21 CFR 201.319 covers water-soluble gums used as active ingredients and names glucomannan explicitly: "Reports in the medical literature and data accumulated by the Food and Drug Administration indicate that esophageal obstruction and asphyxiation have been associated with the ingestion of water-soluble gums, hydrophilic gums, and hydrophilic mucilloids." The rule applies "when marketed in a dry or incompletely hydrated form", and lists the covered dosage forms without ranking them: "Capsules, granules, powders, tablets, and wafers." The mandated warning reads:

"Taking this product without adequate fluid may cause it to swell and block your throat or esophagus and may cause choking. Do not take this product if you have difficulty in swallowing. If you experience chest pain, vomiting, or difficulty in swallowing or breathing after taking this product, seek immediate medical attention."

Health Canada goes further down the gut. Its direction for all glucomannan products states that "taking this product with insufficient liquid may result in choking, or blockage/obstruction of the throat, esophagus or intestine." Intestinal obstruction is part of the warned-about risk, not just the swallowing part.

The regulations trace to published cases, both of which Health Canada cites for its own contraindications. A 1986 report in the British Medical Journal was titled, plainly, "Glucomannan and risk of oesophageal obstruction". A 2007 case report in Clinical Toxicology describes "a 37-year-old female who developed delayed esophageal obstruction after ingesting an over-the-counter diet aid containing glucomannan" — she cleared it by forceful vomiting just before scheduled endoscopy, and was later found to have an oesophageal web. Its authors conclude that the case "illustrates the potential dangers of glucomannan and other hygroscopic medications in patients with a history of upper gastrointestinal pathology."

How much is too much

The highest intake any of these regulators authorises is Health Canada's laxative dose, 0.5–5 g three times per day — a ceiling of 15 g a day, adults 18 and over only. Everything else sits far below it: 3 g/day for the EU weight-loss claim, 4 g/day for the EU cholesterol claim, 3–4.5 g/day in Health Canada's cholesterol range. Nothing in these documents supports the "more fibre must be better" instinct. Each dose must be taken with "at least 250 ml of liquid", plus adequate fluid across the day.

Who should not take it

Health Canada's monograph is the clearest checklist available.

• Do not use if you have difficulty swallowing.
• Do not use if you have fever or any undiagnosed gastrointestinal trouble.
• Stop use if hypersensitivity or allergy occurs.
• Ask a health professional before use if you are pregnant or breastfeeding. The monograph gives this caution without stating a reason, and no trial in this article studied pregnancy.
• Ask a health professional before use if you have diabetes or a lazy bowel.
• Seek care immediately if you get chest pain, vomiting, or difficulty swallowing or breathing after taking it.
• For laxative use, stop and ask a professional "if symptoms worsen or if laxative effect does not occur within 7 days". Do not keep escalating the dose past a week of nothing happening.
• Children: the monograph's entire dose table is for adults 18 and over, so glucomannan should not be given to a child or teenager without professional advice. The recent trial in this age group is a reason for caution as well as a null result: in 96 children aged 6–17 given 3 g/day for 12 weeks there was no effect on BMI-for-age z-score (MD 0.0, 95% CI −0.1 to 0.1), and "the blood pressure was greater at 12 weeks (systolic) and at 24 weeks (diastolic) in the glucomannan group."

Medicines and blood sugar

Viscous fibre in the gut can slow drug absorption, and this has been measured directly. In nine healthy volunteers given 2.5 mg of glibenclamide with breakfast, adding 3.9 g of konjac powder blunted the plasma peak from 76.4 ± 25.0 ng/mL to 31.7 ± 24.5 ng/mL at 30 minutes and from 120.9 ± 56.0 to 51.3 ± 35.5 ng/mL at 60 minutes. The same study found something that matters more than the absorption curve: "Mean plasma glucose concentration was significantly lower at 30 min in the test experiment than in the control despite the lower level of plasma glibenclamide." Less drug in the blood, and yet lower blood sugar — the fibre was pushing glucose down on its own. If you take a glucose-lowering medicine, that is an additive effect to raise with your prescriber before you start, not after.

Health Canada's general rule is deliberately broad and covers supplements as well as drugs: "Take a few hours before or after taking other medications or health products." The 2007 case report lists "possible modification of the bioavailability of other medications" among glucomannan's known negative effects, without naming any. Beyond glibenclamide, no interaction with a specific drug has been quantified in the sources cited here — so the spacing rule is the whole of the reliable advice, and lists of interacting drugs you see elsewhere are extrapolation.

Everyday side effects

Health Canada's expected-effects line is simple: "When using this product you may experience temporary gas and bloating." In the Keithley trial these were mild: belching in 13.4% of glucomannan observations versus 4.1% on placebo, bloating 12.7% versus 3.7%, stomach fullness 11.9% versus 2.4%. They "were transient, lasting for only 1-2 hours after taking glucomannan on the first 1–3 study days, and did not lead to study discontinuation." Liver enzymes and creatinine stayed normal.

If you still want to try it, do it like this

Two defensible reasons exist to buy a konjac glucomannan supplement: lowering LDL cholesterol, where the evidence is decent, or adding bulk for regularity. Weight loss is a third-order reason at best. If you proceed:

1. Dose to the target you care about, and respect the ceiling. Roughly 3 g/day (1 g before each of three meals) is the intake behind both the EU weight-loss claim and the 10% LDL estimate; the EU cholesterol claim uses 4 g/day; Health Canada lists 1–1.5 g three times daily for cholesterol and 0.5–5 g three times daily for laxative use, adults only. No document here supports going above 15 g/day.
2. Water is a dosing instruction, not a suggestion. At least 250 mL of liquid per dose, plus adequate fluid across the day. This is the variable that separates "mild bloating" from an emergency department.
3. Hydrate the fibre before you swallow it, whatever the format. The FDA rule covers capsules, granules, powders, tablets and wafers alike when dry or incompletely hydrated; no dosage form is exempt. Health Canada's instruction for powders is to "mix well with liquid and drink immediately". If you have any history of swallowing trouble, reflux, strictures or an oesophageal web, the contraindication applies to you and no format makes it safe.
4. Take it 0.5–1 hour before the meal, and during the day rather than immediately before bedtime.
5. Space it from medication and other supplements by a few hours in both directions.
6. Set a review date. Health Canada advises consulting a professional about cholesterol-lowering use beyond eight weeks, and about laxative use that produces nothing within seven days. A fair test at eight weeks is a lipid panel and a weight trend, not a feeling.

How it compares with the other things sold for this job

The 2023 network meta-analysis of 111 RCTs is the fairest available comparison, because every supplement in it was assessed by one team using one method. Its point estimates for weight difference versus placebo: psyllium −3.70 kg (95% CI −5.18 to −2.22), Nigella sativa −2.09 kg, spirulina −1.77 kg, chitosan −1.70 kg, glucomannan −1.36 kg, green tea −1.25 kg, curcumin −0.82 kg. Spirulina carried high certainty; curcumin, psyllium, chitosan and Nigella sativa moderate; glucomannan and green tea only low, and the authors' overall verdict was that these supplements "can result in a small weight loss in adults with overweight or obesity". Psyllium — another viscous soluble fibre — outranked glucomannan on both the estimate and the certainty grade. A 2004 systematic review that included glucomannan among eleven supplements had already reached a blunter verdict on the category: "None of the reviewed dietary supplements can be recommended for over-the-counter use." If your goal is purely the number on the scale, that is the honest comparison to sit with before you buy a bottle of glucomannan capsules or powder.

Short answers to the common questions

How much weight will glucomannan actually make me lose?

Between nothing and about 1.4 kg over a typical trial, on top of whatever diet you are already following. No pooled analysis has found an effect large enough to meet a pre-specified clinical-significance threshold.

Is glucomannan safe long-term?

Nobody knows. The trials are short — eight to twelve weeks is typical — and Health Canada advises consulting a clinician for cholesterol-lowering use beyond eight weeks. There is no long-term safety dataset to point at.

Capsules or powder?

The FDA's choking rule draws no distinction: it covers capsules, granules, powders, tablets and wafers alike whenever the product is dry or incompletely hydrated. What varies is how much liquid reaches the fibre before it reaches your oesophagus — which is why Health Canada requires at least 250 mL per dose for every form and tells powder users to mix well with liquid and drink immediately. Capsules are what most trials used; neither format is safe taken dry.

Can I take it with a GLP-1 medication?

Ask the prescriber first. No trial cited here tested that combination, and the one measured interaction shows glucomannan blunting a medicine's absorption while independently lowering blood glucose.

Does it help with blood sugar?

The 2008 meta-analysis found fasting glucose 7.44 mg/dL lower (95% CI −14.16 to −0.72), but noted that "patients with impaired glucose metabolism did not benefit from glucomannan to the same degree." The Keithley trial found no glucose effect at all. Health Canada tells people with diabetes to consult a professional before use. Treat it as unsettled, and as potentially additive to your medication rather than a benefit to bank on.

References

1. Safety and Efficacy of Glucomannan for Weight Loss in Overweight and Moderately Obese Adults, Journal of Obesity, 2013
2. The Efficacy of Glucomannan Supplementation in Overweight and Obesity: A Systematic Review and Meta-Analysis of Randomized Clinical Trials, Journal of the American College of Nutrition, 2014
3. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis, American Journal of Clinical Nutrition, 2008
4. The effect of glucomannan on body weight in overweight or obese children and adults: a systematic review of randomized controlled trials, Nutrition, 2015
5. Correction of data errors and reanalysis of "The effect of glucomannan on body weight in overweight or obese children and adults", Nutrition, 2015
6. Efficacy of dietary supplements containing isolated organic compounds for weight loss: a systematic review and meta-analysis of randomised placebo-controlled trials, International Journal of Obesity, 2021
7. Comparative effects of nutraceuticals on body weight in adults with overweight or obesity: a systematic review and network meta-analysis of 111 randomized clinical trials, Pharmacological Research, 2023
8. Dietary supplements for body-weight reduction: a systematic review, American Journal of Clinical Nutrition, 2004
9. A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan on LDL cholesterol, non-HDL cholesterol and apolipoprotein B, American Journal of Clinical Nutrition, 2017
10. Effect of glucomannan on obese patients: a clinical study, International Journal of Obesity, 1984
11. No Effect of Glucomannan on Body Weight Reduction in Children and Adolescents with Overweight and Obesity: A Randomized Controlled Trial, The Journal of Pediatrics, 2019
12. Effect of glucomannan on functional constipation in children: a systematic review and meta-analysis of randomised controlled trials, Asia Pacific Journal of Clinical Nutrition, 2017
13. 21 CFR 201.319 — Water-soluble gums, hydrophilic gums, and hydrophilic mucilloids as active ingredients; required warnings and directions, US Food and Drug Administration / Government Publishing Office, 2023
14. Glucomannan monograph, Natural Health Products Ingredients Database, Health Canada, 2024
15. Annex to Commission Regulation (EU) No 432/2012 — list of permitted health claims made on foods, legislation.gov.uk, 2012
16. Glucomannan and risk of oesophageal obstruction, British Medical Journal, 1986
17. Esophageal obstruction from a hygroscopic pharmacobezoar containing glucomannan, Clinical Toxicology, 2007
18. Effect of dietary fiber, glucomannan, on absorption of sulfonylurea in man, Hormone and Metabolic Research, 1983